186
Participants
Start Date
June 24, 2016
Primary Completion Date
November 14, 2016
Study Completion Date
November 10, 2017
linaclotide
Oral administration once daily
Placebo
Oral administration once daily
Site JP00029, Aichi
Site JP00030, Aichi
Site JP00021, Chiba
Site JP00022, Chiba
Site JP00023, Chiba
Site JP00024, Chiba
Site JP00040, Fukuoka
Site JP00001, Hokkaido
Site JP00002, Hokkaido
Site JP00037, Hyōgo
Site JP00038, Hyōgo
Site JP00039, Hyōgo
Site JP00017, Kanagawa
Site JP00018, Kanagawa
Site JP00019, Kanagawa
Site JP00020, Kanagawa
Site JP00031, Osaka
Site JP00032, Osaka
Site JP00033, Osaka
Site JP00034, Osaka
Site JP00035, Osaka
Site JP00036, Osaka
Site JP00025, Saitama
Site JP00026, Saitama
Site JP00027, Saitama
Site JP00028, Saitama
Site JP00003, Tokyo
Site JP00004, Tokyo
Site JP00005, Tokyo
Site JP00006, Tokyo
Site JP00007, Tokyo
Site JP00008, Tokyo
Site JP00009, Tokyo
Site JP00010, Tokyo
Site JP00011, Tokyo
Site JP00012, Tokyo
Site JP00013, Tokyo
Site JP00014, Tokyo
Site JP00015, Tokyo
Lead Sponsor
Astellas Pharma Inc
INDUSTRY